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Abstract
Introduction: Prevalence of chronic kidney disease (CKD) amongst intensive care unit (ICU) admissions is rising.
How mortality and risk of end-stage renal disease (ESRD) differs between those with and without CKD and with
acute kidney injury (AKI) is unclear. Determining factors that increase the risk of ESRD is essential to optimise
treatment, identify patients requiring nephrological surveillance and for quantification of dialysis provision.
Method: This cohort study used the Swedish intensive care register 2005–2011 consisting of 130,134 adult patients.
Incomplete cases were excluded (26,771). Patients were classified (using diagnostic and intervention codes as well
as admission creatinine values) into the following groups: ESRD, CKD, AKI, acute-on-chronic disease (AoC) or no
renal dysfunction (control). Primary outcome was all-cause mortality. Secondary outcome was ESRD incidence.
Results: Of 103,363 patients 4,192 had pre-existing CKD; 1389 had ESRD; 5273 developed AKI and 998 CKD patients
developed AoC. One-year mortality was greatest in AoC patients (54 %) followed by AKI (48.7 %), CKD (47.6 %) and
ESRD (40.3 %) (P < 0.001). Five-year mortality was highest for the CKD and AoC groups (71.3 % and 68.2 %,
respectively) followed by AKI (61.8 %) and ESRD (62.9 %) (P < 0.001). ESRD incidence was greatest in the AoC and
CKD groups (adjusted incidence rate ratio (IRR) 259 (95 % confidence interval (CI) 156.9–429.1) and 96.4, (95 % CI
59.7–155.6) respectively) and elevated in AKI patients compared with controls (adjusted IRR 24 (95 % CI 3.9–42.0);
P < 0.001). Risk factors independently associated with ESRD in 1-year survivors were, according to relative risk ratio,
AoC (356; 95 % CI 69.9–1811), CKD (267; 95 % CI 55.1–1280), AKI (30; 95 % CI 5.98–154) and presence of elevated
admission serum potassium (4.6; 95 % CI 1.30–16.40) (P < 0.001).
Conclusions: Pre-ICU renal disease significantly increases risk of death compared with controls. Subjects with AoC
disease had extreme risk of developing ESRD. All patients with CKD who survive critical care should receive a
nephrology referral.
Trial registration: Clinical trials registration number: NCT02424747 April 20th 2015.
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Introduction
As the demographic of the intensive care unit (ICU)
population changes, more patients present with pre-
existing renal dysfunction [1, 2]. Chronic kidney disease
(CKD) is defined by the Kidney Disease Improving Glo-
bal Outcomes (KDIGO) as an abnormality of kidney
function or structure present for more than 3 months,
and is classified according to glomerular filtration rate
(GFR) and proteinuria to stages 1–5. Patients in stage 5
who have a loss of renal function (GFR <15 ml/min per
1.73 m2) requiring dialysis are referred to as having end-
stage renal disease (ESRD) [3]. CKD and ESRD are asso-
ciated with increased risk of hospitalisation, cardiovascu-
lar disease and death compared with individuals without
renal dysfunction, and these diagnoses may affect out-
comes following ICU admission [4–7]. How the risk of
death for patients with CKD and ESRD differs from
those with de novo acute kidney injury (AKI), and what
impact acute-on-chronic disease (AoC) may have, has
not been fully investigated in ICU populations. A num-
ber of studies have addressed mortality in hospitalised
and community-based populations with renal dysfunc-
tion; however, outcomes may not be generalisable to the
ICU where the panorama of diseases and illness severity
precipitating admission differ [8, 9]. Studies of ICU pa-
tients often lack comparison ICU cohorts and few have
described long-term follow-up. Evidence suggests that
illness severity scoring systems may overestimate mortal-
ity risk in ICU patients with pre-existing renal impair-
ment [2, 10]. This may lead to overly negative
prognostication and restrictive treatment. Emerging evi-
dence suggests that ICU outcomes for patients with
ESRD may be better than previously assumed and super-
ior to survival in patients with AKI [11, 12].
How factors related to ICU admission are associated
with ESRD risk has not been fully elucidated. In a large
Danish cohort, AoC was found to increase the risk of
ESRD compared with CKD per se; surprisingly, de novo
AKI was found to carry a greater cumulative risk of
ESRD than isolated CKD [13]. Identification of pre-ICU
risk factors, such as premorbid CKD and other co-
morbidities, combined with intra-ICU risk factors such
as AoC and de novo AKI is essential to improve treat-
ment strategies during critical care and to identify pa-
tients who merit continuing nephrological surveillance.
This is vital because, unfortunately, post-ICU nephro-
logical follow-up of patients with pre-existing renal dys-
function or de novo AKI is not currently routine
practice in Sweden or in many other countries.
The Swedish Intensive care register (SIR) database has
near complete coverage of all Swedish ICU admissions.
The use of SIR and other national registers allowed reli-
able identification both of subjects with pre-ICU renal
dysfunction and uniquely a control population with no
recorded renal disease prior to, or whilst in, ICU. We
previously used this cohort to examine risk of death and
post-ICU renal impairment in patients without premor-
bid renal disease suffering from AKI [14]. In the present
study we aimed to determine the long-term risk of death
and ESRD in ICU patients with and without pre-existing
renal dysfunction and to compare their risks to patients
with AKI and with those who develop AoC disease.
Additionally, we aimed to identify premorbid and ICU
admission parameters predicting development of ESRD




We used prospectively collected data from SIR and other
Swedish national health registries. The Stockholm re-
gional ethics committee granted ethical approval and in-
formed consent was deemed unnecessary due to the
scale and observational nature of the study. The study
was performed in accordance with the ethical standards
laid down in the 1964 Declaration of Helsinki and its
later amendments.
Study cohort
We conducted an observational study from January
2005 to January 2010, using data from SIR. We included
all first ICU admissions of adult patients (>18 years). We
excluded patients with missing disease severity scores,
intervention codes and/or diagnosis codes for AKI from
International Classification of Diseases version 10 (ICD-
10).
We used the unique 10-digit Swedish identification
number to cross-link SIR data with the following
national registers, previously described in detail [14]
and in (Additional file 1):
1. The Swedish cause of death register to obtain details
of all-cause mortality.
2. The national patient register (NPR) was utilised to
obtain the subjects comorbidities using ICD-10
codes which we then classified according to the
Charlson comorbidity index [15].
3. The Swedish renal register (SRR) provided data on
individuals with ESRD prior to and post-ICU
admission.
Primary outcome was mortality up to 5 years. Second-
ary endpoint was ESRD.
Definitions
We classified patients based on their pre-ICU renal sta-
tus as having no renal disease, CKD or ESRD. Premorbid
creatinine levels or GFR estimates were not available
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Patients were identified as having CKD if ICD-10 codes
for moderate to severe renal disease according to the
Charlson criteria (detailed in Additional file 2) were
present in NPR. Current SRR guidelines recommend
that only patients with CKD grade 3b or higher should
be registered in NPR; these cases are patients with severe
CKD. ESRD was recorded if subjects were registered in
the SRR. Subjects were further grouped according to the
presence or absence of AKI during ICU admission. Pa-
tients with no prior renal dysfunction who fulfilled any of
the criteria below were recorded as having de novo AKI
and are referred to hereafter as AKI. Subjects with pre-
morbid CKD additionally meeting criteria 1, 2 or 3 below
were considered to have AoC disease. Patients with no re-
corded renal disease are referred to as the control group,
whilst patients in the CKD, ESRD and AKI groups are
collectively described as having renal dysfunction.
Criteria for AKI:
1. Intermittent haemodialysis (IHD) or continuous
renal replacement therapy (CRRT) reported
in SIR.
2. The diagnosis “acute renal failure” recorded within
the Acute Physiology and Chronic Health Evaluation
(APACHE) II score, defined as a creatinine increase
by >1.5 times from baseline (known to the
diagnosing doctor) with urine output <410 ml in
24 hours.
3. Diagnosis code “acute kidney failure” N17 in ICD-10
assigned at discharge.
4. A serum creatinine >354 μmol/l (KDIGO grade 3)
recorded on admission in APACHE II, Simplified
Acute Physiology Score (SAPS)-II or SAPS-III
scoring systems.
Patients were considered to have developed ESRD if
they were registered in the SRR 3 months or more after
admission to ICU.
Data from the Swedish cause of death register was avail-
able until 31 December 2011 and maximum follow-up for
primary outcome was 7 years. Data from other national
registers were available until 31 December 2010 and
therefore the maximum follow-up for secondary analysis
was 6 years.
Statistical analysis
We report continuous data as medians with interquartile
range (IQR). Categorical data are expressed as counts
and percentages. The Mann–Whitney test was used to
compare distributions of continuous variables at baseline
between each group and the no renal disease (control)
cohort. The Fisher’s exact test was used to compare
prevalence of comorbidities between groups. A two-
sided P value <0.05 was considered significant.
Primary analysis
We considered time from ICU admission to death or
end of follow-up (31 December 2011 for death or 31
December 2010 for secondary analysis), whichever
occurred first. Information regarding emigration was
unavailable. Survival curves were estimated by the
Kaplan-Meier method and the log-rank test was used
to verify equality of survivor functions between sub-
groups. We tested for proportionality of survival
curves using Schoenfeld residuals and found evidence
of non-proportionality; proportional hazard regression
was therefore inappropriate and we instead used Pois-
son regression, which more easily allowed modelling
time varying covariates and non-proportional hazards.
We present incidence rate ratios (IRR).
Multivariable analysis
Potential confounders were considered on the basis of
prior knowledge of AKI and CKD and on whether inclu-
sion of the covariates to the models changed estimates
of log relative risk by >10 % [16]. We selected and tested
age, sex, SAPS-III score (the scoring system most often
recorded), acute surgery and the Charlson comorbidity
groups as potential confounders and adjusted for these
in our sensitivity analysis of subgroups. We present two
models of multivariable analyses for primary outcome: a
fully adjusted model which includes SAPS-III score
(Model 2) and a partially adjusted model (Model 1),
Fig. 1 Flow chart of SIR cohort and excluded cases. AKI Acute
kidney injury, SIR Swedish Intensive care register
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Table 1 Baseline characteristics of the cohort according to renal disease status
Baseline characteristics All No renal disease AKI P value ESRD P value Chronic only P value Acute-on-chronic P value
n = 10,363 n = 92,509 n = 5273 n = 1389 n = 3194 n = 998
Demographics
Age in years, mean (SD) 60.2 (19.3) 59.3 (19.6) 67.9 (14.2) <0.001 61.1 (14.3) <0.001 71.1 (13.6) <0.001 70.4 (11.4) <0.001
Age in years, median (IQR) 64 (47–76) 63 (45–75) 70 (61–78) 63 (52–72) 63 (52–72) 72 (64–81)
Length of ICU stay (hours), median (IQR) 24 (13–60) 23 (12–53) 68 (26–189) <0.001 26 (15–58) <0.001 27 (15–63) <0.001 64 (25–156) <0.001
Women, n (%) 44,480 (43.0) 40,411 (43.6) 2086 (39.6) <0.001 500 (36.0) <0.001 1140 (35.7) <0.001 343 (34.4) <0.001
Admissions per patient, mean (SD) 1.3 (0.88) 1.31 (0.89) 1.29 (0.74) 0.19 1.36 (0.86) <0.001 1.35 (0.88) 0.005 1.30 (0.74) 0.55
Admissions per patient, median (IQR) 1 (1–1) 1 (1–1) 1 (1–1) 1 (1–1) 1 (1–1) 1 (1–1)
Laboratory dataa (median values given with IQR, n denotes number of patients in whom this data was available)
Highest potassium (mmol/l) 4.2 (3.9–4.6) 4.1 (3.9–4.5) 4.7 (4.1–5.5) <0.001 4.8 (4.2–5.5) <0.001 4.4 (4.0–5.0) <0.001 4.9 (4.3–5.7) <0.001
n 18,743 16,069 1605 273 534 262
Highest sodium (mmol/l) 139 (136–142) 139 (136–142) 137 (134–141) <0.001 138 (135–140) <0.001 139 (136–142) 0.65 138 (135–141) <0.001
n 18,792 16,121 279 270 535 262
Lowest sodium (mmol/l) 136 (133–139) 136 (133–139) 133 (130–137) <0.001 134 (132–137) 136 (133–140) 134 (130–137)
n 18,797 16,121 1604
Highest bilirubin (μmol/l) 10 (6–18) 10 (6–17) 14 (8–26) <0.001 10 (6–17) 0.92 10 (7–17) 0.42 12(7–22) <0.001
n 19,797 16,863 1768 207 633 326
Lowest arterial pH 7.36 (7.29–7.41) 7.36 (7.30–7.41) 7.29 (7.19–7.38) <0.001 7.35 (7.2–7.4) <0.001 7.34 (7.25–7.4) <0.001 7.28 (7.17–7.36) <0.001
n 47,318 40,449 3968 598 1586 717
Lowest bicarbonate (mmol/l) 22 (19–25) 23 (20–25) 18 (14–22) <0.001 23 (19–24) 0.213 21 (18–25) 0.002 19(14–21) <0.001
n 4566 3662 593 62 134 115
Maximum creatinine (μmol/l) 85 (65–125) 80 (63–105) 254 (164–422) <0.001 460 (275–673) <0.001 185 (129–277) <0.001 363 (238–553) <0.001
n 54,655 47,441 4076 660 1738 740
Maximum urea (mmol/l) 8 (4.9–14.3) 6.7 (4.3–10.1) 17.5 (11–26) <0.001 19.4 (15–25) <0.001 16.6 (11.9–24.5) <0.001 27 (19.3–36.6) <0.001
n 3519 2717 532 62 104 104
Lowest thrombocyte count (× 109/l) 228 (166–296) 230 (170–296) 199 (123–291) <0.001 217 (153–286) 0.003 220 (152–292) <0.001 203 (131–277) <0.001
n 37,438 32,586 2695 421 1217 519
Disease severity scoring system (median values given with IQR, n denotes number of patients in whom this data was available)
APACHE II score 15 (9–22) 14 (8–20) 25 (20–32) <0.001 22 (17–28) <0.001 19 (14–26) <0.001 27 (21–33) <0.001










Table 1 Baseline characteristics of the cohort according to renal disease status (Continued)
SAPS-II score 27 (0–44) 25 (0–41) 55 (42–70) <0.001 35 (16–52) <0.001 40 (23–53) <0.001 56 (43–68) <0.001
n 17,074 15,376 764 269 503 162
SAPS-III score 54 (44–65) 52 (43–63) 68 (59–77) <0.001 60 (51–71) <0.001 64 (55–72) <0.001 69 (60–78) <0.001
n 20,970 18,326 1437 195 736 276
Interventionsb
Invasive mechanical ventilation, n (%) 8621 (8.3) 7155 (7.7) 994 (18.9) <0.001 93 (6.7) 0.156 201 (6.3) 0.002 178 (17.8) <0.001
Acute surgery, n (%) 8379 (8.1) 7282 (7.8) 662 (12.6) <0.001 109 (7.8) 1.0 228 (7.14) 0.132 98 (9.82) 0.029
Elective surgery, n (%) 5889 (5.7) 5237 (5.7) 295 (5.6) 1.0 83 (6.0) 0.6 201 (6.3) 0.111 69 (6.9) 0.098
Comorbidities
Charlson comorbidity score, meanc (SD) 2,03 (2.42) 1.8 (2.2) 2.6 (2.5) <0.001 5.2 (2.5) <0.001 5.8 (2.6) <0.001 5.6 (2.6) <0.001
Charlson score with renal points
removed, mean (SD)
1.92 (2.3) 1.78 (2.2) 2.6 (2.5) <0.001 3.2 (2.4) <0.001 3.8 (2.6) <0.001 3.6 (2.6) <0.001
Myocardial infarction, n (%) 14,605 (14.1) 11,896 (12.9) 986 (18) <0.001 387 (28.0) <0.001 1047 (32.8) <0.001 289 (29.0) <0.001
Congestive cardiac failure, n (%) 16,281 (15.7) 12,521 (13.5) 1324 (25.1) <0.001 438 (31.5) <0.001 1563 (48.9) <0.001 435 (43.6) <0.001
Peripheral vascular disease, n (%) 10,948 (10.6) 8921 (9.6) 704 (13.4) <0.001 348 (25.0) <0.001 761 (23.8) <0.001 214 (21.4) <0.001
Cerebrovascular disease, n (%) 17,742 (17.2) 15,658 (16.9) 808 (15.3) <0.001 310 (22.3) <0.001 789 (24.7) <0.001 177 (17.7) 0.497
Dementia, n (%) 2070 (2.0) 1840 (2.0) 99 (1.9) 0.612 16 (1.2) 0.03 100 (3.13) <0.001 15 (1.50) 0.359
COPD, n (%) 14,841 (14.4) 12,999 (14.1) 808 (15.3) 0.010 150 (10.8) <0.001 696 (21.8) <0.001 188 (18.8) <0.001
Rheumatological disease, n (%) 4006 (3.8) 3311 (3.6) 269 (5.1) <0.001 93 (6.7) <0.001 262 (8.2) <0.001 71 (7.1) <0.001
Peptic ulcer disease, n (%) 6729 (6.5) 5693 (6.2) 423(8.0) <0.001 154 (11.2) <0.001 362 (11.3) <0.001 97 (9.7) <0.001
Cancer, n (%) 18,175 (17.6) 15,726 (17.0) 1262 (24.0) <0.001 217 (15.7) 0.183 738 (23.1) <0.001 232 (23.3) <0.001
Metastatic disease, n (%) 3747 (3.6) 1918 (3.6) 304 (4.7) <0.001 24 (1.7) <0.001 127 (4.0) 0.246 28 (2.8) 0.199
Mild liver disease, n (%) 5272 (5.1) 4504 (4.9) 369 (7.0) <0.001 123 (8.9) <0.001 210 (6.6) <0.001 66 (6.6) 0.015
Moderate or severe liver disease, n (%) 2436 (2.4) 3319 (2.1) 249 (5.8) <0.001 31 (2.2) 0.64 125 (3.9) <0.001 58 (5.8) <0.001
Uncomplicated diabetes, n (%) 16,684 (16.1) 13,168 (14.2) 1372 (26.2) <0.001 537 (38.7) <0.001 1215 (38.0) <0.001 392 (39.3) <0.001
Diabetes with complications, n (%) 6756 (6.5) 4660 (5.0) 523 (9.9) <0.001 499 (35.9) <0.001 806 (25.2) <0.001 268 (26.9) <0.001
Paraplegia, n (%) 2004 (1.9) 1787 (1.9) 90 (1.7) 0.287 29 (2.07) 0.624 78 (2.44) 0.043 20 (2.00 0.817
HIV, n (%) 137 (0.13) 125 (0.14) 4 (0.08) 0.328 3 (0.22) 0.44 5 (0.16) 0.63 0 (0) 0.65
aLaboratory data was obtained from the severity scorings systems APACHE II, SAPS-II and SAPS-III. APACHE II and SAPS-II record the highest or lowest values during the first 24 hours of ICU admission, whilst SAPS-III records
values from 1 hour before until 1 hour after ICU admission. Values for scoring systems were not available in all patients; n denotes the number of patients in which this information was recorded
bIntervention codes were also underreported and therefore the number of patients in which these data were available is detailed in the table. Reporting of all other baseline characteristics is complete
cCharlson score is not age adjusted
P values compared to no renal disease group
AKI Acute kidney injury, APACHE Acute Physiology and Chronic Health Evaluation, COPD Chronic obstructive pulmonary disease, ESRD End-stage renal disease, IQR Interquartile range, SAPS Simplified Applied Physiology










which excluded SAPS-III score. Some covariates only
significantly changed log relative risk in the fully ad-
justed model in the presence of SAPS III and are there-
fore not present in model 1.
Survival percentiles
Laplace regression was used to estimate the number of
days of survival to event (death or ESRD) for the fifth,
tenth, twentieth and thirtieth centiles in all groups [17].
Secondary analysis
Secondary analyses were performed in a similar manner
to the primary analysis. Time from admission to ESRD
was considered, with censoring occurring at the point of
death or end of follow-up, whichever occurred first. A
multivariable analysis model is presented for secondary
outcome.
Additionally, a polynomial logistic regression was per-
formed to identify predictors of development of ESRD at
1 year in 1-year survivors. The model included no cen-
sored data. All patients were followed up for at least
1 year; that is, no patient was censored before the end of
the first year. This competing risks model included four-
level polytomous outcomes defined as death, ESRD, ESRD
and death or no negative outcome, with the latter being
the reference outcome. Stepwise backwards elimination
was used to construct the model at the significance level
of P > 0.1. Covariates were selected on the basis of a priori
knowledge of AKI and CKD and covariates which changed
estimates of log relative risk by >10 %, including available
laboratory data and comorbidities and demographic data.
Relative risk ratios (RRR) are reported because mul-
tiple outcomes were possible. RRR are the ratio of rela-
tive risks for the outcome ESRD versus base category
(survival without ESRD) for each given covariate pattern
compared with a reference category. This reference cat-
egory was male, with no comorbidities (according to
Charlson index), normal admission potassium (3.9–4.59
mmol/l) and no renal disease (pre- or peri-ICU).
The polytomous (competing risk) model enabled pre-
diction of the probability of the outcome ESRD occur-
ring and allowed creation of a binary variable ESRD/no
ESRD. The sensitivity and specificity of this prediction
was investigated with respect to this binary outcome by
using the receiver operating characteristic (ROC) curve.
The area under the ROC curve (AUC) was used to as-
sess discrimination.
Analysis was performed using Stata version 12 (Stata-
Corp LP, College Station, TX, USA).
Results
We identified 130,134 first admissions between 2005
and 2011. A flow chart detailing case exclusion is shown
in Fig. 1. A total of 103,363 patients were included in
the final analyses. Baseline characteristics and outcome
for patients excluded due to insufficient data are pre-
sented in Additional file 3.
Overall, 4,192 (4.1 %) patients had pre-morbid CKD.
Of these, 998 (23.8 %) developed AoC renal disease. In
total, 1389 of 103,363 (1.34 %) patients were identified
as having ESRD prior to admission; 5273 subjects de-
veloped (severe) de novo AKI, whilst the remaining
patients (92,509) were considered to have had no renal
disease. Characteristics of these patients are presented in
Table 1.
The median age of the cohort was 64 years. Patients
with CKD and de novo AKI were significantly older than
controls (74 and 73 years versus 63 years; P <0.001).
The median length of ICU stay (LOS) was greatest for
AKI patients (68 hours) and all groups with renal dys-
function had longer LOS than the controls (23 hours;
P< 0.001). ESRD patients were younger (63 years; P<
0.001) than all other renal disease groups (P values in
Table 1 refer only to comparison of each group to the
no renal disease (control) group). Test of significance be-
tween renal dysfunction groups are not displayed. The
groups with ESRD and CKD had significantly shorter
lengths of stay (26 and 27 hours, respectively) compared
Table 2 Primary outcome; multivariable Poisson regression analysis of risk of death according to renal function status
Group n Deaths Person years Mortality rate deaths/







All 103,363 37,836 2.5 × 105 0.151 (0.150–0.153)
No renal disease 92,509 31,530 2.3 × 105 0.135 (0.134–0.137) 1 1 1
AKI 5273 2943 7.6 × 103 0.387 (0.374–0.402) 2.87 (2.76–2.97) 2.14 (2.06–2.22) 1.15 (1.09–1.21)
Chronic only 3194 2002 4.9 × 103 0.405 (0.387–0.423) 2.99 (2.86–3.13) 1.75 (1.71–1.86) 1.26 (1.17–1.36)
Acute-on-chronic 998 619 1.3 × 103 0.478 (0.442–0.518) 3.53 (3.26–3.33) 2.36 (2.18–2.56) 1.38 (1.24–1.54)
ESRD 1389 782 2.8 × 103 0.281 (0.26–0.30) 2.08 (1.94–2.23) 2.13 (1.98–2.30) 1.46 (1.29–1.67)
MRR are relative to patients in the no renal disease group
aModel 1: adjusted for age, gender, myocardial infarction and diabetes mellitus with complications.
bModel 2: fully adjusted model, adjusted for age, gender, SAPS-III score, myocardial infarction, cerebrovascular disease, diabetes mellitus with complications,
moderate to severe liver disease, cancer and dementia.
AKI Acute kidney injury, CI Confidence interval, ESRD End-stage renal disease, MRR Mortality rate ratio
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to all other renal disease groups (P < 0.001). The cohort
consisted of 43 % women. Men were more likely than
women to have pre-existing renal dysfunction (64 % of
CKD and 64.3 % of ESRD patients were male; P< 0.001).
Illness severity scores were significantly higher in pa-
tients with renal dysfunction versus controls and were
highest in those with AoC renal disease (SAPS-III 69
versus 52; P < 0.001). The group with ESRD had signifi-
cantly lower severity scores than all other renal dysfunc-
tion groups (P < 0.05).
Interventions were underreported, but AKI patients
and the AoC group differed from controls by having
higher rates of invasive ventilation (18.9 and 17.8 versus
7.7 %; P < 0.001) and emergency surgery (12.6 and 9.2
versus 7.8 %; P < 0.001).
Compared with controls, patients with renal dysfunc-
tion had a significantly greater number of comorbidities
and higher Charlson score; CKD subjects had the highest
mean adjusted score (3.8 versus 1.8; P < 0.001). Cardiovas-
cular disease, myocardial infarction, congestive cardiac
disease and diabetes were more common amongst those
with CKD compared with other groups. Subjects with
pre-existing ESRD had less congestive cardiac failure,
COPD and malignant disease than other patients with
renal dysfunction (Table 1).
Primary outcome
Follow-up for primary outcome was up to 7 years, with
a median time of 2.1 years, whilst for secondary out-
come median follow-up was 1.3 years.
During follow-up 37,836 (36.6 %) patients died. Rates
of all-cause crude mortality were highest in patients with
AoC renal disease who had a mortality rate ratio (MRR)
relative to the control group of 3.53 (P < 0.001) and this
differed significantly from subjects with both de novo
AKI and CKD, where MRR compared to controls were
2.87 and 2.99, respectively (P < 0.001) (Table 2). The risk
of death for ESRD patients was elevated compared with
controls (MRR 2.08) but significantly lower than for
patients with both CKD and AKI (P < 0.001). Multivari-
ate analysis reduced estimates of MRR although they
remained significantly elevated in all renal dysfunction
groups compared to controls (P < 0.001). Full adjustment
showed MRR for ESRD to be higher than for AKI (1.46
versus 1.15; P < 0.001).
Kaplan-Meier estimates showed 90-day mortality to be
highest in the AoC and AKI groups (46.2 and 43.5 %)
whilst for the ESRD group it was 29 %. However, this
Table 3 Primary outcome; Kaplan-Meier mortality estimates at specific time points according to renal function status
Group Mortality probability (%)
90 days 95 % CI 1 year 95 % CI 3 years 95 % CI 5 years 95 % CI
No renal disease 19.3 19.1–19.6 24.6 24.4–24.9 29.1 28.8–29.4 39.1 38.7–39.5
AKI 43.5 42.2–44.9 48.7 47.4–50.1 53.0 51.6–54.4 61.8 60.0–64.6
Chronic only 36.8 35.1–38.5 47.7 45.9–49.4 55.7 53.9–57.4 71.3 69.1–73.4
Acute-on-chronic 46.2 43.2–49.3 54.3 51.3–57.4 58.6 55.5–61.8 68.2 64.2–72.2
ESRD 29.0 26.7–31.4 40.3 37.8–42.9 47.0 44.4–49.7 62.9 59.8–66.1
AKI Acute kidney injury, CI Confidence interval, ESRD End-stage renal disease
a 
b 
Fig. 2 Kaplan-Meier curves showing a 5-year survival and b 3-year
risk of developing ESRD according to renal disease status. Note that
official registration of ESRD occurred at least 3 months after ICU ad-
mission and therefore there is a sudden steep decline in curve b
corresponding to this time point. AKI Acute kidney injury, CKD
Chronic kidney disease, ESRD End-stage renal disease, ICU
Intensive care unit
Rimes-Stigare et al. Critical Care  (2015) 19:383 Page 7 of 12
increased to 40.3 % by 1 year and was 62.9 % at 5 years,
similar to the mortality rate for AKI (61.8 %). Patients
with CKD had the highest 5-year mortality rate of
71.3 % (Table 3 and Fig. 2a).
Crude survival for the fifth to thirtieth centiles analysis
(Table 4) shows that 5 % of all patients died within one
day of ICU admission. Twenty percent of AKI and AoC
patients were dead within 5 days, whilst the first 20 % of
deaths in the no renal disease group occurred by
117 days. Thirty percent of patients in the AKI, CKD
and AoC groups had died by 11.0, 31.0 and 31.4 days,
respectively. In contrast it took 109 days for the first
30 % of patients in the ESRD group to die.
Secondary outcome
In univariate analysis, incidence of ESRD (Table 5) was
highest in the AoC group (0.138 events per person year)
followed by the CKD groups (0.069 events per person
year; P < 0.001). Crude IRR were 205 and 103, respect-
ively. The proportion of patients with ESRD was 9.13 %
in the CKD group and 19.71 % in AoC subjects at 1 year.
This rose to 21.09 and 25.45 %, respectively, at 5 years.
AKI patients 1-year incidence of ESRD was 2 %, increas-
ing to 3.9 % at 5 years (Table 6; Fig. 2b).
Multivariate analysis showed that ESRD incidence
remained highest in the AoC and CKD group after ad-
justment IRR (259 and 96.4); for subjects with de novo
AKI, risk was also elevated although to a lesser degree
(adjusted IRR 24; P < 0.001; Table 5).
The competing-risks multinomial regression analysis
showing predictors of ESRD at 1-year post-ICU admis-
sion in 1-year survivors with RRR is presented in Table 7
(predictors of other outcomes used only in order to con-
struct the model are not presented). The RRR showed
the predicted risk of developing ESRD versus survival
with no ESRD. For patients with CKD it was 265.7 times
higher than for those without CKD. For the AoC group
it was 356.6 times higher than for patients with no renal
disease.
The area under the ROC curve (presented in Fig. 3)
from the predicted value of the multinomial logistic
regression was 0.937 (95 % CI 0.87–1.00). Significant
predictors were high serum potassium on admission
(RRR 4.61; 95 % CI 1.29–16.38) and presence of pre-
ICU CKD )RRR 265.7; 95 % CI. 55.2–1279), AKI (30.3;
95 % CI. 5.98–154.5) or AoC (365; CI 95 % 69.9–
1818). Age was not associated with likelihood of
ESRD; it was modelled using cubic splines and cate-
gorised by 20-year intervals, as patients over 80 were
less likely to receive chronic dialysis than younger
patients. Congestive heart failure was found to be
negatively associated with the risk of ESRD at 1 year;
it was associated with death at 1-year (P < 0.001).
Discussion
We explored long-term risks of mortality and ESRD in
more than 100,000 ICU patients with or without pre-
morbid CKD. Compared with patients without renal disease
we found that the CKD group had a threefold crude in-
creased risk of death, the AoC group had 3.5-fold, the ESRD
group 2.1-fold and the AKI group 2.9-fold higher mortality.
In ICU survivors, subjects with CKD prior to admis-
sion had significantly elevated risk of developing ESRD
in comparison to ICU controls. The highest risk was
seen in the AoC group who had 259 times higher ad-
justed risk of developing dialysis dependence than the
control group, whilst those with CKD had a 96-fold ele-
vated risk of ESRD.
Our finding that subjects with CKD, and particularly
AoC, had higher mortality rates compared with those
with AKI is consistent with most other studies. A study
of 9450 surgical patients found long-term survival to be
significantly worse for those with AoC than for patients
with AKI (hazard ratio (HR) 3.3) [8]. In a second study,
Lebiedz et al. found the presence of AKI in patients with
nondialysis-dependent CKD to be associated with 1-year
mortality [18]. However, an observational cohort of 618
AKI patients from the PICCARD study reported better
crude survival for patients with pre-existing CKD than
for subjects without [19]. It was noted that these pa-
tients received earlier nephrological referral; perhaps
prompt assessment led to earlier intervention.
Table 4 Primary outcome; crude survival centiles derived from Laplace regression according to renal function status
Group Crude survival (days) for each given centile (95 % CI)
5th 10th 20th 30th
No renal disease 1.0 (0–2.0) 5.9 (4.6–7.3) 117 (108–125) 745 (725–765)
AKI 0.76 (0–2.4) 1 (0–3.6) 4 (0.8–7.0) 11 (7.5–14.5)
Chronic only 1.0 (0–4.4) 2.0 (0–7.4) 9.0 (2.5–15.5) 31.0 (23.7–38.3)
Acute-on-chronic 1 (0–4.9) 1.2 (0–7.8) 4.6 (0–12.8) 13 (3.6–22.4)
AKI on CKD 1.0 1.3 4.6 31.4
ESRD 1.0 (0–7.8) 2.8 (0–10.8) 20.3 (10.0–30.7) 109.0 (72.2–145.7)
AKI Acute kidney injury, CI Confidence interval, CKD Chronic kidney disease, ESRD End-stage renal disease
Rimes-Stigare et al. Critical Care  (2015) 19:383 Page 8 of 12
Mortality in our study was relatively low for ESRD pa-
tients (90-day mortality, 29 %) compared with two previ-
ous studies, where 90-day mortality rates were 42 and
44.6 % [20, 21].We also found that crude mortality was
lower for ESRD patients compared with AKI patients
(1 year 40.3 % versus 48.7 %; P > 0001). However, this
survival advantage was not maintained after adjustment,
indicating presence of selection bias. Our ESRD popula-
tion was younger, less severely ill, and had less comor-
bidity than other renal disease groups. Ostermann and
co-workers found their ESRD population to be affected
by fewer organ failures and less likely to be mechanically
ventilated [22]. ESRD patients selected for admittance to
ICU may represent a healthier subgroup of the ESRD
population usually presenting with less severe disease
than other patients. A cohort of 41,972 UK and German
ICU admissions found lower mortality in ESRD than
AKI patients (hospital mortality 34.5 % versus 61.6 %;
P < 0.0001) [22]. Reviews examining this and other
studies found survival to be better for ESRD patients
than for AKI groups as did two subsequent original
studies [11, 12, 23–25].
The most striking finding of this study was the ex-
treme relative risk of ESRD in patients with CKD prior
to ICU admission, in particular for those with AoC. This
occurred despite the high competing risk of death in
these groups and was confirmed by the competing risk
analysis. These observations are concordant with a large
cohort which found AoC patients (without renal recov-
ery at discharge) to have a HR of 213 for developing
ESRD, compared with patients with preserved kidney
function [8]. Ishani et al. reported a HR of 41.2 for AoC
(79.5 cases per 1000 patients) compared with controls in
a cohort of over 233,000 elderly hospitalised patients [9].
Another community-based study of over 39,000 individ-
uals found dialysis-requiring AoC increased the risk of
developing ESRD by 30 % compared with CKD without
AKI [26]. Clearly CKD patients have a much higher risk
than the general population of developing ESRD and the
risk is directly proportional to GFR reduction. Risk of
developing ESRD for CKD patients has been quantified
in two studies as being between 4.14 and 6.37 per 1000
person years [27, 28]. Our findings of an ESRD IR per
1000 person years of 69.0 for CKD and 138 for AoC pa-
tients admitted to ICU (presented in Table 5 as events
per person year) is clearly far greater than the risk attrib-
utable to natural progression of CKD alone.
The model of covariates predicting ESRD at 1 year in
survivors produced an AUC of 94 %; this simple model
is more discriminatory than any currently available novel
biomarkers at identifying risk of ESRD [29, 30]. Model-
ling of ESRD is complex due to the fact that ESRD is
not purely a biological endpoint (as GFR measurement
is); it requires acceptance to a treatment programme,
which excludes patients on the basis of old age or
comorbidity.
This study has limitations; it was affected by underre-
porting, a problem common to most register studies of
this magnitude. AKI diagnosis, interventions and in par-
ticular renal replacement therapy, were not always re-
corded, meaning that we were not exhaustively able to
identify all patients with AKI and AoC disease. However,
cases where these diagnoses were recorded should repre-
sent those with the most severe disease. As a result,
some patients with mild acute disease may have been
misclassified to no renal disease or CKD only groups.
Table 5 Secondary outcome; multivariable Poisson regression for risk of developing ESRD according to renal disease status
Group Patients (n) Events (n) Person years IR event/person year (95 % CI) Crude IRR (95 % CI) Adjusted IRRa (95 % CI)
No renal disease 92,509 116 1.7 × 10 5 0.0007 (0.0006–0.0008) 1 1
AKI 5273 65 5.2 × 10 3 0.0125 (0.0098–0.0160) 18.6 (13.7–25.2) 24.1 (13.9–42.0)
Chronic only 3194 237 3.4 × 10 3 0.069 (0.0611–0.0788) 103 (82.5–128.6) 96.4 (59.7–155.6)
Acute-on-chronic 998 111 803.1 0.1382 (0.1147–0.1665) 205.1 (158.1–266.1) 259 (156.9–429.1)
aAdjusted for Simplified Applied Physiology Score version 3 score, age, gender and diabetes and dementia.
CI Confidence interval, IR Incidence rate, IRR Incidence rate ratio
Table 6 Secondary outcome; Kaplan-Meier estimates of likelihood of developing ESRD at specific time points according to renal
disease status
Group Probability of ESRD (%)
90 days 95 % CI 1 year 95 % CI 3 years 95 % CI 5 years 95 % CI
No renal disease 0.04 0.03–0.06 0.08 0.06–0.10 0.20 0.16– 0.25 0.30 0.24–0.38
AKI 1.67 1.25–2.22 2.03 1.56–2.65 2.95 2.18–3.98 3.88 2.72–5.51
Chronic only 5.95 4.98–7.10 9.13 7.88–10.57 16.56 14.38–19.03 21.09 17.92–24.73
Acute-on-chronic 15.82 12.93–19.28 19.71 16.45–23.52 25.45 20.92–30.76 25.45 20.92–30.76
AKI acute kidney injury, ESRD End-stage renal disease, CI 95 % confidence interval
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This would result in a type one error bringing differ-
ences between groups towards the null. Despite this, sta-
tistically significant differences were observed between
the cohorts suggesting that identification of subjects was
predominantly correct. We identified patients previously
diagnosed with CKD using the NPR, but baseline cre-
atinine and GFR measurements were unavailable, and
thus some subjects may have suffered from undiagnosed
CKD prior to admission to the ICU. Additionally it was
not possible to acertain the exact CKD grade.
We excluded individuals with insufficient data for AKI
categorisation. Analysis of the excluded subjects revealed
that they were younger, with lower disease severity and
had shorter LOS than the studied cohort (Additional
file 3). Excluded subjects seemingly represent a healthier
group, with less AKI and AoC disease; their mortality
rates were significantly lower than in the study cohort.
As a matter of convention, we present the SAPS-III
score in our fully adjusted regression model. However,
one of the components of SAPS-III is creatinine which
itself was used to define AKI and non-AKI groups. We
were unable to remove “renal points” which may lead to
over-adjustment. Similarly, including other covariates
common to SAPS-III such as age, acute surgery and ma-
lignancy in regression models may compound risk of
over-adjustment.
The strengths of this study lie in the use of well vali-
dated, reliable national databases, which allowed us to
categorise subjects based on pre-ICU renal status and al-
most uniquely permitted identification of a large ICU
control population for comparison. Completeness of
outcome data enabled us to accurately describe long-
term mortality and ESRD incidence. Thus, we suggest
that the study has a high degree of internal validity. The
scale of the cohort and high coverage of ICU admissions
from both general and speciality ICUs should allow gen-
eralisation to other national ICU populations making the
external validity of our study high.
Conclusion
In one of the largest studies examining the effect of pre-
ICU renal disease status on outcome after ICU, we dem-
onstrated that ESRD patients have mortality similar to
that of AKI subjects. These patients may represent a
healthier subsection of the ESRD cohort. Nonetheless,
overly negative prognostication for this group is not
merited. Patients with prior CKD and particularly AoC
were demonstrated to have elevated risk of death and a
Table 7 Competing risks model for predicting risk of ESRD in 1-
year ICU survivors by polynomial multivariable logistic regression
analysis
Covariate Relative risk ratioa (95 % CI) P value
Female gender 1.12(0.48–2.63) 0.787




AKI 30.4 (5.98–154) <0.001
CKD 265.7 (55.1–1280) <0.001
AoC 356.6 (69.9–1811) <0.001
Reference category =male, no comorbidity (according to Charlson index),
admission potassium (3.9–4.59), no renal disease
aRisk of ESRD versus survival without ESRD relative to the reference category
AKI Acute kidney injury, AoC Acute-on-chronic kidney disease, CI Confidence
interval, CKD Chronic kidney disease
Fig. 3 Area under the receiver operating characteristic (ROC) curve for competing-risk model predicting likelihood of ESRD among 1-year survivors
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strikingly high relative risk of developing ESRD. These
results establish that nephrological follow-up is impera-
tive for all CKD patients surviving critical care and in
particular those with AoC and those with elevated potas-
sium on admission. Clearly the implications for planning
and provision of nephrology and dialysis facilities are
substantial because increasing numbers of CKD patients
are being admitted to ICU with a greatly elevated risk of
developing ESRD.
Key messages
 Patients presenting to ICU with pre-existing renal
dysfunction have a high risk of death and of
developing ESRD. Patients with CKD who survive
ICU should receive nephrological follow-up.
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